Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$86 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6
Industry P/E
--
EV/EBITDA
-8.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
33,527,858
CFO
$-41.02 Mln
EBITDA
$-86.12 Mln
Net Profit
$-93.38 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| -18.3 | -14.4 | -18.3 | -6.6 | -16.0 | -11.7 | -1.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| 34.5 | -40.0 | -8.7 | 43.1 | -3.3 | -6.4 | -16.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
2.6 | 85.5 | 0.0 | -10.3 | -- | -64.5 | -- | 6.0 |
| 1.0 | 3.8 | 0.0 | -7.0 | -- | -187.1 | -- | 1.8 | |
| 5.8 | 80.1 | 57.9 | -2.3 | -4.1 | -57 | -- | 19.2 |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T... cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Read more
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
Headquarters
San Jose, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Anixa Biosciences Inc (ANIX) is $2.55 (NASDAQ) as of 02-Apr-2026 18:11 EDT. Anixa Biosciences Inc (ANIX) has given a return of -15.98% in the last 3 years.
Since, TTM earnings of Anixa Biosciences Inc (ANIX) is negative, P/E ratio is not available.
The P/B ratio of Anixa Biosciences Inc (ANIX) is 6.05 times as on 02-Apr-2026, a 52 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Anixa Biosciences Inc (ANIX) are Rs 5.46 and Rs 2.33 as of 05-Apr-2026.
Anixa Biosciences Inc (ANIX) has a market capitalisation of $ 86 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Anixa Biosciences Inc (ANIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.17
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.